These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 25281755)

  • 21. Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial.
    LaForce C; Man CY; Henderson FW; McElhaney JE; Hampel FC; Bettis R; Kudule L; Harris J; Yates P; Tisdale M; Webster A
    Clin Ther; 2007 Aug; 29(8):1579-90; discussion 1577-8. PubMed ID: 17919541
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial.
    Watanabe A; Chang SC; Kim MJ; Chu DW; Ohashi Y;
    Clin Infect Dis; 2010 Nov; 51(10):1167-75. PubMed ID: 20936975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza.
    Taylor WR; Thinh BN; Anh GT; Horby P; Wertheim H; Lindegardh N; de Jong MD; Stepniewska K; Hanh TT; Hien ND; Bien NM; Chau NQ; Fox A; Ngoc NM; Crusat M; Farrar JJ; White NJ; Ha NH; Lien TT; Trung NV; Day N; Binh NG
    PLoS One; 2008; 3(10):e3410. PubMed ID: 18923671
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children.
    Sugaya N; Tamura D; Yamazaki M; Ichikawa M; Kawakami C; Kawaoka Y; Mitamura K
    Clin Infect Dis; 2008 Aug; 47(3):339-45. PubMed ID: 18582202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study.
    Trevejo JM; Asmal M; Vingerhoets J; Polo R; Robertson S; Jiang Y; Kieffer TL; Leopold L
    Antivir Ther; 2018; 23(4):335-344. PubMed ID: 29244026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Delayed oseltamivir treatment is associated with longer viral shedding of pandemic (H1N1) 2009 virus.
    Leung YH; Lim WL; Wong MH; Chuang SK
    Epidemiol Infect; 2012 May; 140(5):814-7. PubMed ID: 21801465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
    Ikematsu H; Kawai N
    Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial.
    Madhi SA; Dittmer S; Kuwanda L; Venter M; Cassim H; Lazarus E; Thomas T; Liberty A; Treurnich F; Cutland CL; Weinberg A; Violari A
    AIDS; 2013 Jan; 27(3):369-79. PubMed ID: 23032417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Virus load kinetics and resistance development during oseltamivir treatment in infants and children infected with Influenza A(H1N1) 2009 and Influenza B viruses.
    Rath B; von Kleist M; Tief F; Karsch K; Tuerk E; Muehlhans S; Louis F; Skopnik H; Schweiger B; Duwe S
    Pediatr Infect Dis J; 2012 Sep; 31(9):899-905. PubMed ID: 22581220
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine.
    Vesikari T; Karvonen A; Korhonen T; Edelman K; Vainionpää R; Salmi A; Saville MK; Cho I; Razmpour A; Rappaport R; O'Neill R; Georgiu A; Gruber W; Mendelman PM; Forrest B;
    Pediatr Infect Dis J; 2006 Jul; 25(7):590-5. PubMed ID: 16804427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of oral oseltamivir for influenza prophylaxis in transplant recipients.
    Ison MG; Szakaly P; Shapira MY; Kriván G; Nist A; Dutkowski R
    Antivir Ther; 2012; 17(6):955-64. PubMed ID: 22728756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pandemic Influenza A (H1N1) 2009 in India: duration of virus shedding in patients under antiviral treatment.
    Gandhoke I; Rawat DS; Rai A; Khare S; Ichhpujani RL
    Indian J Med Microbiol; 2011; 29(1):37-41. PubMed ID: 21304193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The virologist and the flu.
    Wicker S; Rabenau HF
    J Clin Virol; 2015 Aug; 69():200-2. PubMed ID: 26209407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prophylactic and therapeutic combination effects of rimantadine and oseltamivir against influenza virus A (H3N2) infection in mice.
    Simeonova L; Gegova G; Galabov AS
    Antiviral Res; 2012 Aug; 95(2):172-81. PubMed ID: 22617756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal clearance of seasonal influenza A viral RNA measured by real-time polymerase chain reaction in patients identified at a hospital emergency department.
    Nilsson AC; Brytting M; Serifler F; Björkman P; Persson K; Widell A
    Scand J Infect Dis; 2010 Sep; 42(9):679-86. PubMed ID: 20507261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection.
    Ling LM; Chow AL; Lye DC; Tan AS; Krishnan P; Cui L; Win NN; Chan M; Lim PL; Lee CC; Leo YS
    Clin Infect Dis; 2010 Apr; 50(7):963-9. PubMed ID: 20180701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential evolution of peripheral cytokine levels in symptomatic and asymptomatic responses to experimental influenza virus challenge.
    McClain MT; Henao R; Williams J; Nicholson B; Veldman T; Hudson L; Tsalik EL; Lambkin-Williams R; Gilbert A; Mann A; Ginsburg GS; Woods CW
    Clin Exp Immunol; 2016 Mar; 183(3):441-51. PubMed ID: 26506932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6-59 months of age.
    Mallory RM; Yi T; Ambrose CS
    Vaccine; 2011 Jun; 29(26):4322-7. PubMed ID: 21513761
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determinants of antiviral effectiveness in influenza virus A subtype H5N1.
    Chan PK; Lee N; Zaman M; Adisasmito W; Coker R; Hanshaoworakul W; Gasimov V; Oner AF; Dogan N; Tsang O; Phommasack B; Touch S; Bamgboye E; Swenson A; Toovey S; Dreyer NA
    J Infect Dis; 2012 Nov; 206(9):1359-66. PubMed ID: 22927451
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiviral drugs in influenza: an adjunct to vaccination in some situations.
    Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.